A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia

Annals of Hematology

Volumn 88, Issue 1, 2009, Pages 85-88

  Tempescul, Adrian ^a   Feuerbach, Johanna ^a   Ianotto, Jean Christophe ^a   Dalbies, Florence ^a   Marion, Veronique ^a   Le Bris, Marie Josée ^b   De Braekeleer, Marc ^b   Berthou, Christian ^a  

^a CHU MORVAN   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; METHOTREXATE; MITOXANTRONE; MYC PROTEIN; PENTOSTATIN; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ASTHENIA; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME TRANSLOCATION; DYSPNEA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; LABORATORY TEST; LETTER; LEUKEMIA REMISSION; LEUKOCYTOSIS; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; SPLENOMEGALY; THROMBOCYTOPENIA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, PROLYMPHOCYTIC, B-CELL; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; VIDARABINE;

EID: 57049150914     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0541-5     Document Type: Letter

References (12)

1. Robak T, Robak P (2007) Current treatment options in prolymphocytic leukaemia. Med Sci Monit 13(4):RA69-RA80
2. Kuriakose P, Perveen N, Maeda K, Wiktor A, Van Dyke DL (2004) Translocations (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukaemia. Cancer Genet Cytogenet 150(2):156-158
3. Crisostomo RH, Fernandez JA, Caceres W (2007) Complex caryotype including chromosomal translocation (8;14)(q24;q32) in one case with B-cell prolymphocutic leukaemia. Leuk Res 31(5):699-701 doi: 10.1016/ j.leukres.2006.06.010
4. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M et al (2005) Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: Evidence for a common origin. Cancer Genet Cytogenet 159(1):74-78 doi: 10.1016/j.cancergencyto.2004.09.016
5. Hercher C, Robain M, Davi F, Garand R, Flandrin G, Valensi F et al (2001) Groupe Français d'Hématologie Cellulaire-"A multicentric study of 41 cases of B-prolymphocytic leukemia: Two evolutive forms". Leuk Lymphoma 42(5):981-987 doi: 10.3109/ 10428190109097717
6. Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A (1999) B-cell prolymphocytic leukaemia: A survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 33(1-2):169-179
7. Taylor HG, Butler WM, Rhoads J, Karcher DS, Detrick-Hooks B (1982) Prolymphocytic leukemia: Treatment with combination chemotherapy to include doxorubicin. Cancer 49:1524-1529 doi: 10.1002/ 1097-0142(19820415)49:8<1524::AID-CNCR2820490803>3.0.CO;2-U
8. Sibbald R, Catovsky D (1979) Complete remission in prolymphocytic leukaemia with the combination chemotherapy CHOP. Br J Haematol 42(3):488-490 doi: 10.1111/j.1365-2141.1979.tb01159.x
9. Montillo M, Tedeschi A, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A et al (2003) Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97:114-120 doi: 10.1002/cncr.11000
10. Mourad YA, Taher A, Chehal A, Shamseddine A (2004) Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol 83(5):319-321 doi: 10.1007/s00277-003-0805-z
11. Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD (2002) Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 43(1):149-151 doi: 10.1080/ 10428190210178
12. Chaar BT, Petruska PJ (2007) Complete response to Alemtuzumab in a patient with B prolymphocytic leukaemia. Am J Hematol 82(5):417 doi: 10.1002/ajh.20843